New Clinical Trial for Treatment of Mesothelioma

Friday, March 6th, 2009

Morphotek has announced the beginning of a phase II clinical trial investigating the efficacy of the monoclonal antibody MORAb-009 for the treatment of mesothelioma. The study will evaluate progression-free survival in patients with advanced pleural mesothelioma who are being receiving MORAb-009 in combination with the standard mesothelioma treatment regimen, pemetrexed + cisplatin.
Continue Reading >

Labels: Mesothelioma, Treatments
Link to this article

Contributing Author

Wade Rawlins is a former environmental reporter with the Raleigh News & Observer.

Editorial Board

Mike Dayton, Editor
Nancy Meredith, Writer
Aaron Phelps, Writer
Lisa Vaughn, Contributor

Latest News

Rise in Asbestos Use in U.S. Increases Urgency to Ban Cancer Causing Fiber
Presence of Asbestos in Schools is National Scandal, British Group Says
Scientists Urge Better Understanding of Nanomaterials to Avoid Introducing 21st Century Asbestos into Society
Elevated Rate of Lung Cancer Among Carolina Textile Workers Exposed to Asbestos, Study Says
Searching For The Fingerprints of Mesothelioma To Detect Cancer Early
Families of Asbestos Workers At Risk of Mesothelioma From Exposure At Home
CanBas Developing Mesothelioma Drug to Enhance Chemotherapy Treatment
Researchers Use Common Cold Virus to Fight Malignant Mesothelioma
Dying Woman’s Request For Canada to Stop Exporting Asbestos and Mesothelioma
Mesothelioma Patient Celebrates Remission of Asbestos Cancer

Ten Facts About Asbestos and Mesothelioma...

AboutMesothelioma.Net